Evaluation of 4-carbethoxy-5(3,3-dimethyl-1-triazeno)-2-phenylimidazole (NSC-166721) and 4-carbethoxy-5-(3,3-dimethyl-1-triazeno)-2-methylimidazole (NSC-166722) as potential antitumor agents.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001562:Benzimidazoles / Q000627:therapeutic use*; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005622:Friend murine leukemia virus; D007093:Imidazoles / Q000627:therapeutic use* / Q000633:toxicity; D007942:Leukemia, Experimental / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010954:Plasmacytoma / Q000188:drug therapy*; D051381:Rats; D014226:Triazenes / Q000627:therapeutic use* / Q000633:toxicity
D000970:Antineoplastic Agents; D001562:Benzimidazoles; D007093:Imidazoles; D014226:Triazenes